Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Siegel, 2014, Cancer statistics, 2014, CA Cancer J Clin, 64, 9, 10.3322/caac.21208 Society AC, 2016 Lacey, 2009, vol. 2, 601 Liu, 2014, New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances, Clin Cancer Res, 20, 5150, 10.1158/1078-0432.CCR-14-1312 Luvero, 2014, Treatment options in recurrent ovarian cancer: latest evidence and clinical potential, Ther Adv Med Oncol, 6, 229, 10.1177/1758834014544121 Della Pepa, 2015, Ovarian cancer standard of care: are there real alternatives?, Chin J Cancer, 34, 17, 10.5732/cjc.014.10274 Davis, 2014, "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?, Gynecol Oncol, 133, 624, 10.1016/j.ygyno.2014.02.038 Symeonides, 2015, Ovarian cancer molecular stratification and tumor heterogeneity: a necessity and a challenge, Front Oncol, 5, 229, 10.3389/fonc.2015.00229 Jansen, 2015, Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer, Pteridines, 26, 41, 10.1515/pterid-2015-0005 Elnakat, 2004, Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Adv Drug Deliv Rev, 56, 1067, 10.1016/j.addr.2004.01.001 Assaraf, 2014, The folate receptor as a rational therapeutic target for personalized cancer treatment, Drug Resist Updat, 17, 89, 10.1016/j.drup.2014.10.002 Ledermann, 2015, Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments, Ann Oncol, 26, 2034, 10.1093/annonc/mdv250 Kalli, 2008, Folate receptor alpha as a tumor target in epithelial ovarian cancer, Gynecol Oncol, 108, 619, 10.1016/j.ygyno.2007.11.020 Wu, 1999, Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix, Cancer Epidemiol Biomarkers Prev, 8, 775 Toffoli, 1998, Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer, Int J Cancer, 79, 121, 10.1002/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V Chen, 2012, Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response, Mol Oncol, 6, 360, 10.1016/j.molonc.2011.11.010 Salazar, 2007, The folate receptor: what does it promise in tissue-targeted therapeutics?, Cancer Metastasis Rev, 26, 141, 10.1007/s10555-007-9048-0 Spannuth, 2010, Farletuzumab in epithelial ovarian carcinoma, Expert Opin Biol Ther, 10, 431, 10.1517/14712591003592069 Gokhale, 2013, Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent, Drug Dev Ind Pharm, 39, 1315, 10.3109/03639045.2012.728226 Dosio, 2010, EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers, Curr Opin Investig Drugs, 11, 1424 Ambrosio, 2014, Vintafolide (EC145) for the treatment of folate-receptor-alpha positive platinum-resistant ovarian cancer, Expert Rev Clin Pharmacol, 7, 443, 10.1586/17512433.2014.909723 Vergote, 2016, A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse, J Clin Oncol, 34, 2271, 10.1200/JCO.2015.63.2596 2014 Chari, 2008, Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc Chem Res, 41, 98, 10.1021/ar700108g Lambert, 2013, Drug-conjugated antibodies for the treatment of cancer, Br J Clin Pharmacol, 76, 248, 10.1111/bcp.12044 Chari, 2014, Antibody-drug conjugates: an emerging concept in cancer therapy, Angew Chem Int Ed Engl, 53, 3796, 10.1002/anie.201307628 Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124 Lutz, 2015, Targeting the folate receptor for the treatment of ovarian cancer, Transl Cancer Res, 4, 118 Erickson, 2010, Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates, Bioconjug Chem, 21, 84, 10.1021/bc900315y Oroudjev, 2010, Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability, Mol Cancer Ther, 9, 2700, 10.1158/1535-7163.MCT-10-0645 Lopus, 2010, Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules, Mol Cancer Ther, 9, 2689, 10.1158/1535-7163.MCT-10-0644 Ab, 2015, IMGN853, a folate receptor-alpha (FRalpha)–targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors, Mol Cancer Ther, 14, 1605, 10.1158/1535-7163.MCT-14-1095 Bookman, 2009, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup, J Clin Oncol, 27, 1419, 10.1200/JCO.2008.19.1684 du Bois, 2006, J Clin Oncol, 24, 1127, 10.1200/JCO.2005.03.2938 Banerjee, 2011, The role of targeted therapy in ovarian cancer, Eur J Cancer, 47 Suppl 3, S116, 10.1016/S0959-8049(11)70155-1 Colombo, 2015, Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives, Crit Rev Oncol Hematol, 97, 335, 10.1016/j.critrevonc.2015.08.017 Yoshida, 2015, Critical appraisal of bevacizumab in the treatment of ovarian cancer, Drug Des Devel Ther, 9, 2351, 10.2147/DDDT.S83275 Gunderson, 2016, Mirvetuximab soravtansine. Folate receptor alpha (FRa)-targeting antibody drug conjugate, treatment of epithelial ovarian cancer, Drugs Future, 41, 539, 10.1358/dof.2016.041.09.2544475 Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 Nguyen, 1993, Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines, Cancer Invest, 11, 264, 10.3109/07357909309024851 Mo, 2015, Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy, Sci Rep, 5, 10414, 10.1038/srep10414 Kondo, 2010, DNA damage induced by alkylating agents and repair pathways, J Nucleic Acids, 2010, 543531, 10.4061/2010/543531 Imreh, 2011, Chromosomal breaks during mitotic catastrophe trigger gammaH2AX-ATM-p53-mediated apoptosis, J Cell Sci, 124, 2951, 10.1242/jcs.081612 Ye, 2014, Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review, Mater Sci Eng C Mater Biol Appl, 45, 609, 10.1016/j.msec.2014.06.002 Economopoulou, 2009, Histone H2AX is integral to hypoxia-driven neovascularization, Nat Med, 15, 553, 10.1038/nm.1947 Wrann, 2013, HIF mediated and DNA damage independent histone H2AX phosphorylation in chronic hypoxia, Biol Chem, 394, 519, 10.1515/hsz-2012-0311 Vergote, 2015, Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications, Cancer Metastasis Rev, 34, 41, 10.1007/s10555-014-9539-8 Peethambaram, 2015, A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors, Invest New Drugs, 33, 321, 10.1007/s10637-014-0171-9 Kummar, 2010, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Nat Rev Drug Discov, 9, 843, 10.1038/nrd3216 Markman, 2000, Second-line treatment of ovarian cancer, Oncologist, 5, 26, 10.1634/theoncologist.5-1-26 Pisano, 2013, Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer, J Drug Deliv, 2013, 898146, 10.1155/2013/898146 Gladieff, 2012, Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial, Ann Oncol, 23, 1185, 10.1093/annonc/mdr441 Reddy, 2014, Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs, Clin Cancer Res, 20, 2104, 10.1158/1078-0432.CCR-13-2423 Kovtun, 2006, Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen, Cancer Res, 66, 3214, 10.1158/0008-5472.CAN-05-3973 Ledermann, 2011, Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer, Int J Gynecol Cancer, 21, 763, 10.1097/IGC.0b013e31821b2669 Mahner, 2015, Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer, Front Oncol, 5, 211, 10.3389/fonc.2015.00211 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Arjaans, 2016, VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside, Oncotarget, 7, 21247, 10.18632/oncotarget.6918 Hu, 2002, Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer, Am J Pathol, 161, 1917, 10.1016/S0002-9440(10)64467-7 Gerber, 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies, Cancer Res, 65, 671, 10.1158/0008-5472.671.65.3 Fujita, 2007, Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma, Oncol Rep, 18, 47